JP2005518789A5 - - Google Patents

Download PDF

Info

Publication number: JP2005518789A5
Authority: JP; Japan
Prior art keywords: antibody; psma; seq; region; amino acid
Prior art date: 2003-01-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2003564202A

Other languages

English (en)

Japanese (ja)

Other versions

JP2005518789A (ja

Filing date

2003-01-28

Publication date

2006-03-02

2003-01-28 Application filed filed Critical

2003-01-28 Priority claimed from PCT/US2003/002448 external-priority patent/WO2003064606A2/fr

2005-06-30 Publication of JP2005518789A publication Critical patent/JP2005518789A/ja

2006-03-02 Publication of JP2005518789A5 publication Critical patent/JP2005518789A5/ja

Status Pending legal-status Critical Current

Links

102000004965 antibodies Human genes 0.000 description 43
108090001123 antibodies Proteins 0.000 description 43
229920001481 poly(stearyl methacrylate) Polymers 0.000 description 23
210000004027 cells Anatomy 0.000 description 20
102100008453 FOLH1 Human genes 0.000 description 16
101700036477 FOLH1 Proteins 0.000 description 16
101700008337 PSMA Proteins 0.000 description 15
125000003275 alpha amino acid group Chemical group 0.000 description 14
230000001404 mediated Effects 0.000 description 13
229920001850 Nucleic acid sequence Polymers 0.000 description 9
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 9
230000000875 corresponding Effects 0.000 description 8
230000003013 cytotoxicity Effects 0.000 description 7
231100000135 cytotoxicity Toxicity 0.000 description 7
230000001419 dependent Effects 0.000 description 7
210000002540 Macrophages Anatomy 0.000 description 6
206010057249 Phagocytosis Diseases 0.000 description 6
210000004602 germ cell Anatomy 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
230000008782 phagocytosis Effects 0.000 description 6
238000003752 polymerase chain reaction Methods 0.000 description 6
238000002965 ELISA Methods 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
210000001616 Monocytes Anatomy 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000038129 antigens Human genes 0.000 description 4
108091007172 antigens Proteins 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000006011 modification reaction Methods 0.000 description 4
241001465754 Metazoa Species 0.000 description 3
102220408563 NANS H22F Human genes 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002934 lysing Effects 0.000 description 3
210000004369 Blood Anatomy 0.000 description 2
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
230000035693 Fab Effects 0.000 description 2
229960000310 ISOLEUCINE Drugs 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
229960005190 Phenylalanine Drugs 0.000 description 2
WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
238000003505 heat denaturation Methods 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
102000005614 monoclonal antibodies Human genes 0.000 description 2
108010045030 monoclonal antibodies Proteins 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
210000004881 tumor cells Anatomy 0.000 description 2
239000004474 valine Substances 0.000 description 2
239000004475 Arginine Substances 0.000 description 1
229960001230 Asparagine Drugs 0.000 description 1
229960005261 Aspartic Acid Drugs 0.000 description 1
229920002676 Complementary DNA Polymers 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
102100014610 FCAR Human genes 0.000 description 1
101700041688 FCAR Proteins 0.000 description 1
229960002989 Glutamic Acid Drugs 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
210000004408 Hybridomas Anatomy 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108020004999 Messenger RNA Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
210000000440 Neutrophils Anatomy 0.000 description 1
101700068068 PSM Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
229920000096 Plastarch material Polymers 0.000 description 1
101700016899 SH2B1 Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
210000003462 Veins Anatomy 0.000 description 1
URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical compound C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
238000010805 cDNA synthesis kit Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
102000037240 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000010841 mRNA extraction Methods 0.000 description 1
229920002106 messenger RNA Polymers 0.000 description 1
229960000060 monoclonal antibodies Drugs 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
229920003259 poly(silylenemethylene) Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000004044 response Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000001519 tissues Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1

Images

JP2003564202A 2002-01-28 2003-01-28 前立腺特異性膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体 Pending JP2005518789A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5998902A	2002-01-28	2002-01-28
PCT/US2003/002448 WO2003064606A2 (fr)	2002-01-28	2003-01-28	Anticorps monoclonaux humains de l'antigene d'enveloppe prostatique specifique (psma)

Publications (2)

Publication Number	Publication Date
JP2005518789A JP2005518789A (ja)	2005-06-30
JP2005518789A5 true JP2005518789A5 (fr)	2006-03-02

Family

ID=27658271

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2003564202A Pending JP2005518789A (ja)	2002-01-28	2003-01-28	前立腺特異性膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体

Country Status (10)

Country	Link
EP (1)	EP1519747A4 (fr)
JP (1)	JP2005518789A (fr)
KR (1)	KR20040077889A (fr)
CN (1)	CN1652821A (fr)
AU (1)	AU2003224604B2 (fr)
BR (1)	BR0307216A (fr)
CA (1)	CA2474616A1 (fr)
MX (1)	MXPA04007262A (fr)
NZ (1)	NZ534687A (fr)
WO (1)	WO2003064606A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7105159B1 (en)	1992-11-05	2006-09-12	Sloan-Kettering Institute For Cancer Research	Antibodies to prostate-specific membrane antigen
US6569432B1 (en)	1995-02-24	2003-05-27	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen and uses thereof
US7381407B1 (en)	1996-03-25	2008-06-03	Medarex, Inc.	Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en)	1996-03-25	2005-11-08	Medarex, Inc.	Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US20050215472A1 (en)	2001-10-23	2005-09-29	Psma Development Company, Llc	PSMA formulations and uses thereof
ES2559002T3 (es)	2001-10-23	2016-02-10	Psma Development Company, L.L.C.	Anticuerpos contra PSMA
US20050191293A1 (en) *	2003-12-10	2005-09-01	Shrikant Deshpande	IP-10 antibodies and their uses
EP1766093B1 (fr) *	2004-02-06	2011-06-15	University of Massachusetts	Anticorps diriges contre des toxines de clostridium difficile et utilisations de ces derniers
JP4734319B2 (ja) *	2004-03-19	2011-07-27	イムクローン・リミテッド・ライアビリティ・カンパニー	ヒト抗上皮成長因子受容体抗体
CA2885854C (fr)	2004-04-13	2017-02-21	F. Hoffmann-La Roche Ag	Anticorps anti-p-selectine
EP1791868B1 (fr)	2004-07-01	2011-02-23	Novo Nordisk A/S	Anticorps liant a des recepteurs kir2dl1,-2,-3, sauf kir2ds4 et leur usage therapeutique
EP1836225B1 (fr)	2005-01-06	2011-11-02	Novo Nordisk A/S	Agents de liaison kir et leurs procedes d'utilisation
US7875278B2 (en)	2005-02-18	2011-01-25	Medarex, Inc.	Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
CN101124249B (zh) *	2005-02-18	2011-06-29	米德列斯公司	抗***特异性膜抗原（psma）的人单克隆抗体
CA2970873C (fr) *	2005-05-09	2022-05-17	E. R. Squibb & Sons, L.L.C.	Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies
EP1726650A1 (fr) *	2005-05-27	2006-11-29	Universitätsklinikum Freiburg	Anticorps monoclonaux et fragments d'anticorps monocaténaires contre l'antigène spécifique de surface membranaire de la prostate
ES2397973T3 (es) *	2006-03-14	2013-03-12	Cancer Targeted Technology Llc	Inhibidores peptidomiméticos del PSMA, compuestos que los comprenden y métodos de utilización
US8852630B2 (en)	2008-05-13	2014-10-07	Yale University	Chimeric small molecules for the recruitment of antibodies to cancer cells
DK2326350T3 (da)	2008-09-08	2013-12-16	Psma Dev Company L L C	Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller
NZ591134A (en) *	2008-10-01	2012-08-31	Micromet Ag	Cross-species-specific (human and primate) bispecific single chain antibody that binds both cd3 (epsilon) epitope and prostate specific membrane antigen (pmsa)
CN101891818B (zh) *	2009-01-16	2012-07-25	中国人民解放军第四军医大学	抗人***特异性膜抗原胞外区单链抗体及其应用
EP2419451A4 (fr) *	2009-04-14	2012-11-14	Proscan Rx Pharma Inc	Anticorps dirigés contre l'antigène membranaire spécifique de la prostate
CN103561771B (zh)	2011-03-17	2019-01-04	伯明翰大学	重新定向的免疫治疗
CA2833019A1 (fr)	2011-04-22	2012-10-26	Emergent Product Development Seattle, Llc	Proteines de liaison a un antigene membranaire specifique de la prostate et compositions et procedes associes
RS53818B1 (en)	2012-10-12	2015-06-30	Spirogen Sàrl	PIROLOBENZODIAZEPINI I NJIHOVI conjugated
CA2905181C (fr)	2013-03-13	2020-06-02	Medimmune Limited	Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
CN103333249A (zh) *	2013-06-14	2013-10-02	广州康合生物科技有限公司	一种抗***特异性膜抗原（psma）的单克隆抗体及其应用
WO2016037644A1 (fr)	2014-09-10	2016-03-17	Medimmune Limited	Pyrrolobenzodiazépines et leurs conjugués
US10100126B2 (en) *	2015-03-10	2018-10-16	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind PSMA
ES2889906T3 (es)	2015-05-21	2022-01-14	Harpoon Therapeutics Inc	Proteínas de unión triespecíficas y usos médicos
WO2017053469A2 (fr)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Polypeptides de liaison à cd3
KR101704379B1 (ko) *	2015-10-27	2017-02-08	(주)알테오젠	항체-약물 접합체 및 그 제조방법
WO2017164678A2 (fr) *	2016-03-23	2017-09-28	서울대학교산학협력단	Anticorps qui se lie à la protéine d'enveloppe du virus du syndrome de fièvre sévère avec thrombocytopénie, et son utilisation
WO2017201488A1 (fr)	2016-05-20	2017-11-23	Harpoon Therapeutics, Inc.	Protéine de liaison à l'albumine sérique à domaine unique
KR102365977B1 (ko)	2016-05-20	2022-02-22	하푼 테라퓨틱스, 인크.	단일 쇄 가변 단편 cd3 결합 단백질
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
WO2018069289A1 (fr)	2016-10-11	2018-04-19	Medimmune Limited	Conjugués anticorps-médicament associés à des agents thérapeutiques à médiation immunitaire
CA3044659A1 (fr)	2016-11-23	2018-05-31	Harpoon Therapeutics, Inc.	Proteine de liaison a l'antigene membranaire specifique de la prostate
BR112019010602A2 (pt) *	2016-11-23	2019-12-17	Harpoon Therapeutics Inc	proteínas trispecíficas para psma e métodos de uso
EP3589662A4 (fr)	2017-02-28	2020-12-30	Harpoon Therapeutics, Inc.	Protéine monovalente inductible de fixation d' antigène
JP7090347B2 (ja)	2017-05-12	2022-06-24	ハープーンセラピューティクス，インク．	メソテリン結合タンパク質
CA3063362A1 (fr)	2017-05-12	2018-11-15	Harpoon Therapeutics, Inc.	Proteines trispecifiques ciblant la msln et procedes d'utilisation
BR112020007196A2 (pt)	2017-10-13	2020-12-01	Harpoon Therapeutics, Inc.	proteínas triespecíficas e métodos de uso
CR20200195A (es)	2017-10-13	2020-08-14	Harpoon Therapeutics Inc	Proteínas de unión a antigenos de maduraciòn de celulas b
WO2019224275A1 (fr)	2018-05-23	2019-11-28	Adc Therapeutics Sa	Adjuvant moléculaire
US10815311B2 (en)	2018-09-25	2020-10-27	Harpoon Therapeutics, Inc.	DLL3 binding proteins and methods of use
JP2022514262A (ja)	2018-12-17	2022-02-10	レビトープリミテッド	双子型免疫細胞エンゲージャー
WO2021164692A1 (fr) *	2020-02-18	2021-08-26	和铂医药(上海)有限责任公司	Protéine isolée se liant à l'antigène psma et son utilisation
CN115768463A (zh)	2020-02-21	2023-03-07	哈普恩治疗公司	Flt3结合蛋白及使用方法
WO2022079211A1 (fr)	2020-10-16	2022-04-21	Adc Therapeutics Sa	Glycoconjugués
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
US20230201366A1 (en)	2021-11-19	2023-06-29	Adc Therapeutics Sa	Anti-psma conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69426527T2 (de) *	1993-06-09	2001-08-30	Unilever Nv	Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen
US7563874B2 (en) *	1998-08-31	2009-07-21	The Regents Of The University Of California	Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
ES2277846T3 (es) *	1999-07-29	2007-08-01	Medarex, Inc.	Anticuerpos monoclonales humanos para antigeno prostatico especifico.
GB0001448D0 (en) *	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
NZ522700A (en) *	2000-06-16	2006-02-24	Human Genome Sciences Inc	Antibodies that immunospecifically bind to blys
ES2559002T3 (es) *	2001-10-23	2016-02-10	Psma Development Company, L.L.C.	Anticuerpos contra PSMA
AU2003270010A1 (en) *	2002-08-30	2004-03-19	Biorexis Pharmaceutical Corporation	Transferrin fusion protein libraries
CA2508214A1 (fr) *	2002-12-02	2004-06-17	Abgenix, Inc.	Anticorps diriges contre la phospholipase a2 et utilisations

2003
- 2003-01-28 KR KR10-2004-7011643A patent/KR20040077889A/ko not_active Application Discontinuation
- 2003-01-28 JP JP2003564202A patent/JP2005518789A/ja active Pending
- 2003-01-28 AU AU2003224604A patent/AU2003224604B2/en not_active Ceased
- 2003-01-28 WO PCT/US2003/002448 patent/WO2003064606A2/fr active IP Right Grant
- 2003-01-28 EP EP03721280A patent/EP1519747A4/fr not_active Withdrawn
- 2003-01-28 BR BR0307216-9A patent/BR0307216A/pt not_active IP Right Cessation
- 2003-01-28 CN CNA038073714A patent/CN1652821A/zh active Pending
- 2003-01-28 NZ NZ534687A patent/NZ534687A/en unknown
- 2003-01-28 MX MXPA04007262A patent/MXPA04007262A/es unknown
- 2003-01-28 CA CA002474616A patent/CA2474616A1/fr not_active Abandoned

Publication	Publication Date	Title
JP2005518789A5 (fr)	2006-03-02
JP7412521B2 (ja)	2024-01-12	Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
CN107849136B (zh)	2022-04-01	抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
BR112021010402A2 (pt)	2021-08-24	Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
WO2021197359A1 (fr)	2021-10-07	Plateforme de construction d'un anticorps multispécifique
CN109721656B (zh)	2022-10-18	靶向rankl的治疗性抗体
US20210284715A1 (en)	2021-09-16	Coagulation factor viii mimetic protein and uses thereof
JP2023506262A (ja)	2023-02-15	抗ｂｃｍａｃａｒ抗体、コンジュゲートおよび使用方法
JP7357012B2 (ja)	2023-10-05	抗ｂｃｍａｃａｒ抗体、コンジュゲート、および使用方法
CN111742220A (zh)	2020-10-02	检测癌症患者中的肿瘤抗原的诊断性测定法
JP2021518748A (ja)	2021-08-05	カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体
US10584175B2 (en)	2020-03-10	FN14-binding proteins and uses thereof
CN111108120A (zh)	2020-05-05	抗人类血管内皮生长因子受体的抗体及其应用
CN113166264B (zh)	2024-02-27	一种分离的抗原结合蛋白及其用途
CN115850458A (zh)	2023-03-28	一种抗冠状病毒rbd蛋白的抗体、制备方法和应用
CA3227486A1 (fr)	2023-02-23	Domaines et echafaudages vnar desimmunises
AU2022329980A1 (en)	2024-02-15	Deimmunized vnar domains and scaffolds
JP2022540904A (ja)	2022-09-20	ヒトｔｒｅｍ－１に対する抗体およびその使用
WO2017125601A1 (fr)	2017-07-27	Anticorps anti-bsep spécifiques